Clinical Case
An 11-year-old boy was admitted to hospital with symptoms of nausea, edema, fatigability, and inability to lie down, which slowly developed over the past 4 months. Transthoracic echocardiography and an ECG were performed and showed the diagnosis of double-chambered left ventricle (DCLV).
A physical examination showed protrusion of the precordium, soft heart sounds, cardiomegaly, a grade 3/6 systolic murmur at the cardiac apex, and enlargement of the liver to 3 cm below the right costal margin. ECG showed a sinus rhythm with left ventricular hypertrophy. Transthoracic echocardiography demonstrated that the left ventricle was divided into basal and apical chambers by an incomplete fibromuscular septum ( Figure 1A ). The basal chamber, which communicated with the left atrium and the normally positioned aorta, was severely enlarged with an end-diastolic diameter of 80.7 mm. This chamber was abnormally configured to the shape of a ball. The basal and midventricular septum expanded toward the right ventricle. The left ventricular wall and septum had impaired contraction with severe reduction of the left ventricular ejection fraction to 35%. Systolic pressure of the 2 chambers was similar, and the diameter of communication between them was 16.0 mm. There was thinning of the wall of the apical chamber. A DCLV was also shown by cardiac magnetic resonance imaging ( Figure 1B) . The patient's ECG showed sinus rhythm, T-wave changes, and enlargement of the left ventricle and left atrium ( Figure 1C) .
We examined the family members of this patient and found a positive family history. We recruited this family and identified a total of 4 other family members with DCLV. All of these patients were diagnosed by transthoracic echocardiography and cardiac magnetic resonance imaging. The pedigree showed a dominant inheritance pattern (Figure 2A ; III-1 was the proband, whereas I-1, I-2, II-3, II-4, II-5, III-1, III-2, III-3, and III-4 were later assessed). After clinical examination, the same cardiac condition was also found in family members II-3, II-5, and III-3, who had no obvious cardiac symptoms (Figures I, II, and III in the Data Supplement). Family member I-2 had an 8-year history of heart failure and was diagnosed with heart disease in the local hospital. We speculated that she was the founder of the cardiac phenotype of this pedigree in view of the family history and her own disease history. However, we were unable to perform further imaging because of a lack of consent. Transthoracic echocardiogram of family member III-4-a 4-year-old girl-showed some fibromuscular tissue at the left ventricular apex but without division of the left ventricle into 2 chambers ( Figure IV 
Genetic Testing of a Rare Variant in MYH7 by Whole-Exome Sequencing
Two affected family members, II-5 and III-1, were selected for whole-exome sequencing (WES) to explore the genetic makeup for this familial malformation. All exons were captured by the SureSelect Human Exon V4 enrichment kit (Agilent, Santa Clara, CA), followed by high-throughput sequencing on the Illumina Hiseq 2500 platform. We used BWA v0.5.1 1 to align reads to the human reference genome (UCSC hg19). Picard was used to mark and remove duplicates. SAMtools 2 was used to detect single-nucleotide polymorphisms and insertion and deletion, and ANNOVAR 3 was used to annotate all variants. The Merlin program was used to perform a linkage study 4 in this family. Furthermore, we used the Affymetrix Cytoscan 750K Array to check potential candidate copy number variations in this pedigree (2 samples, III-1 and III-3, were selected). Chromosome analysis suite was used to identify the potential pathogenic copy number variations.
The mean read depths of target regions were 78.0× and 55.8×, with 95.7% and 94.5% of bases in target regions covered by >10× for each sample. Variants fulfilling the following criteria were included as follows: (1) missense, nonsense, frameshift, or splicing variants in coding regions that were shared by both affected family members; (2) rare variants with a minor allele frequency <0.1% in 1000Genome, ESP6500si, and the Exome Aggregation Consortium; (3) variants absent from the in-house database (≈400 exomes); and (4) predicted to be deleterious to protein function and structure (PolyPhen, Sorting Intolerant From Tolerant, MutationTaster; Combined MYH7 Rare Variant and Familial DCLV Annotation Dependent Depletion, predicted to be damaging by at least 2 programs) and evolutionary conserved.
Filtration excluded most of the variants identified by WES, with only 29 remaining. Subsequently, we performed segregation analysis using the results from Sanger sequencing of all family members with available DNA (primers are listed in Table I in the Data Supplement). Twenty-four variants were then excluded because they did not cosegregate with the defect. Among the remaining variants (Table II in the Data Supplement) , we further prioritized them by gene function, known candidate diseases, and other related information from Online Mendelian Inheritance in Man (http://omim.org/) and PubMed (https:// www.ncbi.nlm.nih.gov/pubmed). We discovered a novel rare variant in MYH7 (NM_000257: c.A998T, p.D333V, logarithm of the odds of linkage score: 1.163 in this family), which is a causative gene for several heart diseases, including hypertrophic cardiomyopathy, 5 dilated cardiomyopathy, 6 left ventricular noncompaction, 7 and Ebstein anomaly. 8 This rare variant was not found in public databases (1000Genomes, ESP6500si, and the Exome Aggregation Consortium) and in our internal database. In silico programs (PolyPhen2, Sorting Intolerant From Tolerant, and MutationTaster) predicted that this variant is deleterious to the structure and function of the encoded protein and is highly conserved among species ( Figure 2B) . Except for MYH7, we did not find any other potential genetic variants that were candidates of, or causal for, any cardiac anomalies. Additionally, 12 copy number variations were shared by the 2 family members, and 11 genes were involved, but none appeared to be potential candidates (Table III in the  Data Supplement) . Therefore, we hypothesize that the MYH7 rare variant p.D333V is the most likely pathogenetic cause of familial DCLV in this family.
Discussion and Conclusions
The definitive aim of genetic testing is to identify pathogenic mutation of genetic disorders. Conventional techniques, such as Sanger sequencing, are efficient for detecting causal mutation in genetic disease that is caused by a limited number of pathogenic genes. However, these methods are not sufficient for determining heterogenous genetic disease or those in which causal genes have not been identified. Because of the huge progress in next-generation sequencing technology, this technology, especially WES, provides a great opportunity to identify potential causal mutations of monogenic disorders and Mendelian familial diseases. WES analysis is a cost-effective approach for determining precise or even personalized mutations for the tested pedigree, especially for heterogeneous disorders, such as congenital heart disease. WES analysis also helps identify at-risk asymptomatic family members, especially in delayed dominant diseases, such as hypertrophic cardiomyopathy and DCLV.
In the present study, a heterozygous missense rare variant in MYH7, resulting in an amino acid change from aspartic acid to valine at position 333, was identified in a DCLV pedigree. MYH7 encodes the heavy chain of β-cardiac myosin with >500 mutations identified to date. 9 The majority of these mutations cause hypertrophic cardiomyopathy. The effects of p.D333V on the structure and function of myosin or the contractility of cardiac muscles were not addressed in this study. However, other evidence may support the pathogenicity of this rare variant. The amino acid substitution of this variant is localized in a helix domain in subfragment-1 of β-cardiac myosin heavy chain. Another missense mutation, p.E328G in the same helix, was previously identified in a family with hypertrophic cardiomyopathy, suggesting a deleterious effect of the mutations located in this region of myosin. 10 Nearly 500 mutations distributed along MYH7 have been associated with different cardiac anomalies, suggesting a heavy burden of rare nonsynonymous variants in MYH7 to myosin function. On the basis of specific features of the rare variant that were calculated and scored in silico, p.D333V can be classified as putative pathogenic, using the classification criteria defined by the American College of Medical Genetics. 11 An abnormal fibromuscular septum in the left ventricle alone is usually benign and has a minimal effect on the myocardium as reported in previous sporadic cases. However, in our familial cases, the clinical features were more complicated. I-2-the grandmother of the index patient who had DCLV-had heart failure and low exercise capacity for several years. The proband's mother had a history of reduced exercise capacity and mild symptoms of heart failure for 13 years. Importantly, the proband's cardiac function rapidly declined in the following year after initial admission to the hospital, and he died of multiple-system organ failure at 12 years of age, despite medical treatments. The disease history of the proband was similar to the other 2 deceased members. II-1 was diagnosed with cardiovascular disease when she was 10 years old and died of heart failure at 12 years of age. II-2 had palpitation and breathlessness at ≈20 years of age. She experienced heart failure during an induced abortion at a local hospital at 22 years of age and died of heart failure at 25 years of age.
The early death of the 3 family members because of their heart failure and impaired cardiac function in the other members suggested myocardial functional impairment. This impairment might not have been because of the double-chambered malformation by related to an inherited underlying functional and structural defect of the heart. Previous experiments have shown that MYH7 mutations may impair contractility of myofibrils and alter myocardial function. 9 Therefore, we speculated that this family-segregated rare variant affected trabecular absorption in the left ventricle during development of the heart, as well as cardiac muscle contraction. This could then have caused the abnormal structure and dysfunction of the left ventricle.
There are some limitations to our study. First, the MYH7 rare variant was only identified by WES in 1 DCLV family with a small number of patients. No additional genetic evidence was found in any sporadic case or other family because of the rarity of the defect. Interestingly, a previous study of DCLV did not identify any causal mutation, despite testing of the MYH7 gene. This finding may indicate genetic heterogeneity of DCLV and suggests that our findings could only explain, in part, the pathogenicity of DCLV. 12 Second, further functional experiments are important to determine the pathogenicity of the MYH7 mutation that was identified in our study.
In conclusion, this is the first report of familial DCLV and identification of MYH7 as its genetic cause. Additionally, our results provide useful information of MYH7-associated diseases.
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